Table 2

Differences in rSBA vaccine response rate between the ACWY-TT and the Men-PS groups
Antibody ACWY-TT Men-PS Difference in vaccine response rate (ACWY-TT minus Men-PS)
N % N % % [95% CI]
rSBA-MenA 289 82.7 99 69.7 13.00 [3.52, 23.50]
rSBA-MenC 324 94.4 113 90.3 4.18 [−1.03, 11.36]
rSBA-MenW-135 326 96.3 109 91.7 4.58 [−0.07, 11.49]
rSBA-MenY 329 93.0 113 85.0 8.05 [1.72, 16.17]

ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0.

Men-PS = group of participants who received one dose of the MenACWY polysaccharide vaccine at Month 0.

Vaccine response defined as:

• rSBA titre ≥32 at Month 1 for initially seronegative participants (rSBA titre <8).

• rSBA titre at Month 1 ≥4-fold the antibody titre at Month 0 for initially seropositive participants (rSBA titre ≥8).

N = number of participants with pre- and post-vaccination results available (ATP immunogenicity cohort).

% = percentage of participants with a vaccine response.

95% CI = standardised asymptotic 95% confidence interval.

Bold = lower limits of the 95% confidence intervals of the differences in vaccine response rates, which were used to demonstrate non-inferiority.

Borja-Tabora et al.

Borja-Tabora et al. BMC Infectious Diseases 2013 13:116   doi:10.1186/1471-2334-13-116

Open Data